Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis
Yuly López(Barcelona Centre for International Affairs), Ilonka Zsolt(Ferrer Grupo (Spain)), Rafael Cantón(Instituto Ramón y Cajal de Investigación Sanitaria), Domingo Gargallo‐Viola(GlaxoSmithKline (United Kingdom)), Jordi Vilà(Hospital Clínic de Barcelona), Marta Tato(Hospital Universitario Ramón y Cajal)
Cited by 11
Related Papers
The CTX-M β-lactamase pandemic
|Current Opinion in Microbiology|2006|1.1k
CTX-M Enzymes: Origin and Diffusion
|Frontiers in Microbiology|2012|955
CTX-M: changing the face of ESBLs in Europe
|Journal of Antimicrobial Chemotherapy|2006|923
Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe
|Eurosurveillance|2008|800
Dissemination of Clonally Related<i>Escherichia coli</i>Strains Expressing Extended-Spectrum β-Lactamase CTX-M-15
|Emerging infectious diseases|2008|699